ISSN:
1433-7339
Keywords:
Key words Granisetron
;
Tropisetron
;
Ondansetron
;
Emesis
;
Continuous infusion
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin–Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m2), or ondansetron (5.3 mg/m2), or tropisetron (3.3 mg/m2) plus dexamethasone 8 mg/m2. Chemotherapy consisted of CDP (120 mg/m2, 48-h CI) followed by ADM (75 mg/m2, 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m2 (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P〈0.0001). The rate of CP declined from the first to the last day of treatment for both CDP/ADM (61% to 27%, P〈0.0001) and IFO (95% to 43%) cycles (P〈0.0001). When CDP/ADM and IFO are delivered on multiple days by CI, granisetron, ondansetron and tropisetron have the same antiemetic efficacy, which declines from the first day onward through successive days.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s005200050027
Permalink
